FDA approves botulinum toxin A to reduce appearance of wrinkles

07/26/2011 | SkinAndAllergyNews.com

The FDA approved Merz Aesthetics' Xeomin, or incobotulinumtoxinA, for temporarily reducing skin lines and wrinkles. The product is expected to be available in the U.S. next year. Dermatologist and trial investigator Joel Cohen said incobotulinumtoxinA is "more similar than it is different to other products that are on the market, particularly Botox."

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park